IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

Inflammatory Bowel Diseases in Clinical Practice: An Interactive Tutorial for Patient Management 2017
1 AMA PRA Category 1 Credit(s)
Launch Date:
May 03, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Relevant Terms:

Inflammatory bowel diseases; Crohn's disease; Ulcerative colitis

Miguel Regueiro, MD

Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Miguel Regueiro, MD, is chairman of the Department of Gastroenterology and Hepatology and professor of medicine at the Lerner College of Medicine at the Cleveland Clinic.

Hans Herfarth, MD, PhD

Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Hans Herfarth, MD, PhD, is Professor of Medicine at the University of North Carolina. His main interest is clinical IBD studies. Dr. Herfarth is the author of more than 190 journal articles, book chapters, and reviews related to IBD. He is on the editorial board of Inflammatory Bowel Diseases and is the chairman of the Clinical Research Alliance of the Crohn’s & Colitis Foundation.
1. Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases
2. Apply principles of therapeutic management according to clinical symptoms, duration, and severity of disease

A fact sheet from the Crohn’s & Colitis Foundation describes the infliximab and adalimumab biosimilars and other recently approved therapies for IBD: http://www.crohnscolitisfoundation.org/assets/pdfs/recently-approved-treatments.pdf
Reading Resources:
  1. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018;11:1-15. [Epub ahead of print]
  2. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153(3):827-834.
  3. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553-1563.
  4. Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am. 2014;43(3):425-440.
  5. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology. 2014;148(1):37-51.
  6. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994-1004.
Hans Herfarth, MD, PhD, has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.
Miguel Regueiro, MD, has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.
Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. 
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hours. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.
Estimated time to complete: 60 minutes
Medium: Internet

There is no fee for this educational activity.

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. This activity is supported by educational grants from AbbVie Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credits™.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have three attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.